EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma

Katja Seipel, Lynn Benninger, Ulrike Bacher, Thomas Pabst

Therapeutics · 2024

DOI: 10.3390/therapeutics1020009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutics, 2024. Verfasst von Katja Seipel und 3 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Mantle cell lymphoma (MCL) represents a rare B-cell lymphoma subtype with rather high relapse rates. Somatic mutations in the PPM1D gene were shown to be associated with adverse outcomes in patients with diffuse large B-cell lymphoma (DLBCL) who received CD19 CAR-T-cell therapy with tisa-cel, which may also apply to mantle cell lymphoma receiving brexu-cel CAR-T-cells.

Methods

In this study, we determined the prevalence of PPM1D mutations in peripheral blood cells of MCL patients before CAR-T-cell infusion and analyzed the impact of low-frequency PPM1D mutations on efficacy and safety aspects of brexu-cel CAR-T-cell treatment in the first 16 r/r MCL patients enrolled at Inselspital Bern.

Results

The prevalence of low-frequency PPM1D gene mutations was 25%, with variant allele frequencies (VAF) of 0.011 to 0.099. Clinical response was analyzed in the PPM1D mutated (PPM1Dmut) vs. PPM1D wild-type (PPM1Dwt) groups with median progression-free survival of 1 versus 32 months (p = 0.07) and median overall survival of 1.5 vs. 27 months (p = 0.001).

Conclusions

Our data suggest that low-frequency PPM1D gene mutations in peripheral blood cells may predict inferior outcomes in patients with mantle cell lymphoma treated with CAR-T-cell therapy.

Zitieren

APA

Seipel, K., Benninger, L., Bacher, U., & Pabst, T. (2024). Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma. Therapeutics. https://doi.org/10.3390/therapeutics1020009

Vancouver

Seipel K, Benninger L, Bacher U, Pabst T. Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma. Therapeutics. 2024. doi:10.3390/therapeutics1020009

BibTeX
@article{Seipel2024,
  author = {Seipel, Katja and Benninger, Lynn and Bacher, Ulrike and Pabst, Thomas},
  title = {Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma},
  journal = {Therapeutics},
  year = {2024},
  doi = {10.3390/therapeutics1020009}
}
Kostenlos starten →